Category: Business

ソウル半導体、自然光LEDの”SunLike”で世界初の高いアイセーフティ認証

韓国安山市–(BUSINESS WIRE)–(ビジネスワイヤ) — 世界的なLED (発光ダイオード)専業メーカーのSeoul Semiconductor Co., Ltd. (本社:韓国安山市、代表理事:李貞勲、以下「ソウル半導体」)は、太陽の光に最も近い光を発するLEDの”SunLike”が、光源の安全性に関するアイセーフティ認証でRG-1の評価を受け、最高レベルの安全性が認められたと明らかにした。 アイセーフティ認証は、LEDから発せられる波長を分析して、安全性に基づいて等級分けされる認証である。照明の安全性の優先度が非常に高い欧州地域では、アイセーフティ認証が不可欠であり、目で直接見たときに、視力に危険を及ぼす可能性のあるリスクグループ3 (RG-3)以下の光源については、完成品に警告文を記述することを義務化している。 SunLikeは、東芝マテリアル株式会社(本社:神奈川県横浜市、代表取締役社長:青木 克明)のTRI-R技術を応用した自然光LEDで、このたびアイセーフティ認証でRG-1の等級を受けた。 RG-1は、当該光源の下で一生生活を続けても生体学的な危険がない安

NovaBay Pharmaceuticals Reports Third Quarter 2017 Financial Results

EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for lid and lash hygiene in the domestic eye care market, reports financial results for the three and ninth months ended September 30, 2017 and provides a business update. “First off, we are significantly better positioned to support continued Avenova growth having entered into a $10.3 million financing with accredited investors

Aerpio Reports Third Quarter 2017 Financial Results

CINCINNATI–(BUSINESS WIRE)–Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today reported financial results for the third quarter ended September 30, 2017. “Aerpio has made tremendous progress in recent months towards the Company’s vision of becoming a leader in developing and commercializing first-in-class treatments for sight-threatening diseases,” said Dr. Joseph Gardner, Chief Executive Officer. “We

Aerpio Reports Third Quarter 2017 Financial Results

CINCINNATI–(BUSINESS WIRE)–Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today reported financial results for the third quarter ended September 30, 2017. “Aerpio has made tremendous progress in recent months towards the Company’s vision of becoming a leader in developing and commercializing first-in-class treatments for sight-threatening diseases,” said Dr. Joseph Gardner, Chief Executive Officer. “We

BioTime Reports Third Quarter Results and Recent Corporate Accomplishments

ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company developing and commercializing products addressing degenerative diseases, today reported financial results for the third quarter ended September 30, 2017. “BioTime achieved several significant milestones during the third quarter, both in its clinical programs and in the execution of its corporate strategy,” said Adi Mohanty, Co-Chief Executive Officer. “With the additional positive

Novaliq annonce que le premier patient a été randomisé pour participer à son essai ESSENCE de Phase 2b/3 portant sur CyclASol® pour le traitement des signes et des symptômes de la sécheresse oculaire

HEIDELBERG, Allemagne–(BUSINESS WIRE)–Novaliq GmbH, une société pharmaceutique spécialisée possédant une plateforme distribution de médicament perturbatrice qui transforme les substances pharmaceutiques très peu solubles en thérapies efficaces pour des applications en ophtalmologie, a annoncé aujourd’hui avoir entamé la randomisation de patients dans le cadre de son essai clinique ESSENCE de Phase 2b/3, qui doit évaluer CyclASol® pour le traitement des signes et des symptômes de la sécheresse

Novaliq meldet Aufnahme des ersten randomisierten Patienten in Phase-2b/3-Studie ESSENCE zu CyclASol® für die Behandlung der Zeichen und Symptome des trockenen Auges

HEIDELBERG, Deutschland–(BUSINESS WIRE)–Novaliq GmbH, ein spezialisiertes pharmazeutisches Unternehmen mit einer disruptiven Drug-Delivery-Plattform, die schwer lösliche Arzneimittel in wirksame Therapeutika für die Augenheilkunde verwandelt, meldete heute den Beginn der Randomisierung von Patienten für die klinische Phase-2b/3-Studie ESSENCE, in der CyclASol® für die Behandlung der Zeichen und Symptome des trockenen Auges (Dry Eye Disease, DED) beurteilt wird. DED ist eine multifaktorielle u

Global Ophthalmic Devices Market – Industry Forecast to 2025 – Growing Relevance of Technology in Ophthalmology – Research and Markets

DUBLIN–(BUSINESS WIRE)–The “Global Ophthalmic Devices Market Analysis & Trends – Industry Forecast to 2025” report has been added to Research and Markets’ offering. The Global Ophthalmic Device Market is poised to grow at a CAGR of around 4.8% over the next decade to reach approximately $71.9 billion by 2025. Some of the prominent trends that the market is witnessing include increasing elderly population, rising frequency of everyday life related diseases, growing relevance of technology

Optovue Highlights AngioVue Essential OCTA at AAO

NEW ORLEANS–(BUSINESS WIRE)–#AAO2017–Optovue, the global leader in the development of optical coherence tomography (OCT) and OCT angiography (OCTA), will highlight its AngioVue® Essential OCTA capability for general ophthalmology, along with its suite of advanced eye care technology at the upcoming American Academy of Ophthalmology Annual Meeting (AAO), Nov. 11-14 in New Orleans. The company will also host an OCT and OCT Angiography Interpretation Lab offering small group sessions, led by industry exp